On average, sell-side analysts expect that Audentes Therapeutics will post -4.13 earnings per share for the current year.
A number of other equities analysts have also recently issued reports on the company.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Thursday, November 7th. The company had revenue of $459.96 million during the quarter, compared to the consensus estimate of $460.00 million. WEX had a net margin of 3.95% and a return on equity of 18.86%. The business's revenue was down 5.6% compared to the same quarter a year ago. During the same period in the prior year, the business earned ($0.97) EPS. Finally, BMO Capital Markets downgraded shares of Audentes Therapeutics from an "outperform" rating to a "market perform" rating and lifted their price objective for the stock from $47.00 to $60.00 in a report on Tuesday. Piper Jaffray Companies downgraded shares of Audentes Therapeutics from an "overweight" rating to a "neutral" rating and upped their target price for the stock from $55.00 to $60.00 in a research report on Tuesday. On Tuesday, November 19 the stock rating was upgraded by Evercore to "Outperform". One analyst has rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of "Hold" and an average target price of $42.00.
NASDAQ KELYA opened at $21.37 on Friday.
Featured Article: What is the Quick Ratio? The company has market cap of $2.70 billion. The firm has a 50-day moving average price of $27.71 and a 200 day moving average price of $33.11.
The acquisition of Audentes represents a key step in the expansion of the Astellas Focus Area approach, under which Astellas strives to create innovative medicines for diseases with high unmet medical needs by identifying unique combinations of biology and therapeutic modality/technology based on emerging science. Kelly Services's dividend payout ratio is presently 13.22%.
Shares in Astellas fell 1.3% on Tuesday in Tokyo, underperforming a 0.6% decline in the broader market. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the sale, the director now owns 276,044 shares of the company's stock, valued at $8,877,575.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The stock was sold at an average price of $30.00, for a total transaction of $432,780.00. Institutional investors own 98.08% of the company's stock.
Several large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC now owns 2,438 shares of the biotechnology company's stock worth $68,000 after buying an additional 2,241 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Audentes Therapeutics by 1.8% in the 3rd quarter. Great Point Partners LLC raised its position in Audentes Therapeutics by 29.2% during the third quarter. Meeder Asset Management Inc. grew its position in Audentes Therapeutics by 578.5% in the 2nd quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company's stock worth $21,721,000 after purchasing an additional 255,086 shares during the last quarter.
At least one set of analysts agreed with Yasukawa's ambitious vision for the combined company, under which Audentes would continue to operate as an independent subsidiary of Astellas. It provides trained employees for data entry, clerical, and administrative support roles across various industries; schools with instructional and non-instructional employees; support staff for seminars, sales, and trade shows; assemblers, quality control inspectors, and technicians for electronic assembly; maintenance workers, material handlers, and assemblers for light industrial works; scientists, and scientific and clinical research workforce solutions; engineering professionals across various disciplines, including aeronautical, chemical, civil/structural, electrical/instrumentation, environmental, industrial, mechanical, petroleum, pharmaceutical, quality, and telecommunications.